NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 1 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,530,998 | -3.0% | 958,043 | +23.2% | 0.00% | 0.0% |
Q2 2023 | $7,767,374 | +38.1% | 777,512 | +22.7% | 0.00% | 0.0% |
Q1 2023 | $5,625,322 | +87672.2% | 633,517 | +8.5% | 0.00% | 0.0% |
Q4 2022 | $6,409 | -99.9% | 583,742 | +74.4% | 0.00% | 0.0% |
Q3 2022 | $4,362,000 | +68.5% | 334,725 | +63.8% | 0.00% | +100.0% |
Q2 2022 | $2,588,000 | -22.2% | 204,302 | -14.0% | 0.00% | 0.0% |
Q1 2022 | $3,328,000 | -1.2% | 237,525 | +104.1% | 0.00% | 0.0% |
Q4 2021 | $3,369,000 | – | 116,358 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |